RARE DISEASES A–Z · LETTER A
Amyloidosis
Amyloidosis is a group of rare diseases in which a protein that should dissolve instead misfolds, clumps into stiff fibres called amyloid, and settles in organs — the heart, kidneys, nerves, and gut are common targets. Which protein misfolds decides the type of amyloidosis, how it behaves, and how it is treated.
By Dr. Mohamed Ibrahim, MD, PhD — Assistant Professor of Medicine, Transplant Nephrology, University of Maryland School of Medicine · Last reviewed: November 2026
Rare Diseases A–Z is part of the MedicalVideos.com education program. It is produced independently of sponsors, and any future sponsorship will be labelled on the hub.
The guide
The basics
Amyloid deposits stiffen and thicken whatever tissue they land in. In the heart the walls thicken and stiffen, causing breathlessness and heart failure with a heart that squeezes fairly well but cannot relax. In the kidneys, protein leaks into the urine and function declines. In nerves, the result is numbness, burning pain, carpal tunnel syndrome — which can precede heart involvement by years — and dizziness from blood pressure that fails to adjust on standing. Tiredness, weight loss, an enlarged tongue, and easy bruising around the eyes are other clues. Because each symptom is common on its own, amyloidosis is famously diagnosed late; the pattern of several organs misbehaving together is the giveaway.
How it works
Diagnosis has two steps: prove amyloid is present, then type it precisely, because treatments for the types are completely different. A small sample of fat from the abdominal wall or a biopsy of an affected organ is stained with Congo red dye, which shows amyloid's characteristic glow under the microscope. Typing is done by specialised laboratory analysis of the deposit itself. Blood and urine tests look for the abnormal light chains behind AL amyloidosis, and genetic testing distinguishes hereditary ATTR from the age-related wild-type form. Heart scans — ultrasound, MRI, and for ATTR a bone tracer scan — map how much the heart is involved, and staging blood tests estimate how advanced the disease is.
Day to day
Treatment aims to stop new amyloid forming, because existing deposits clear only slowly, if at all. For AL amyloidosis that means chemotherapy-style treatment aimed at the abnormal plasma cells making the light chains, often including antibody therapy and, for suitable patients, stem cell transplantation. For ATTR, medicines that stabilise the transthyretin protein stop it breaking apart into amyloid, and newer gene-silencing injections reduce how much of the protein the liver makes at all. Supportive care runs alongside: careful fluid management for the heart (standard heart-failure tablets are often poorly tolerated in amyloid hearts), rhythm management, and kidney support. Care is coordinated by specialist amyloidosis centres, and referral there matters.
When to get help
Prognosis has improved markedly with modern therapy, and it depends heavily on how much the heart is involved and how early treatment starts. Regular follow-up tracks heart and kidney markers, and for AL disease the light-chain level, which shows whether production has been switched off. Report new breathlessness, fainting, rapid weight gain from fluid, or worsening numbness promptly. Family implications differ by type: hereditary ATTR calls for genetic counselling and offering testing to relatives, while AL and wild-type ATTR are not inherited. Clinical trials are active in this field, and specialist centres can advise on eligibility.
Common questions
What is the difference between AL and ATTR amyloidosis?
In AL amyloidosis the amyloid comes from abnormal light chains made by a clone of plasma cells in the bone marrow — it is treated like a blood condition. In ATTR it comes from transthyretin, a liver transport protein; ATTR is either hereditary (a gene variant) or wild-type, developing with age, mainly in the heart.
Can amyloid deposits be removed?
There is no established treatment that dissolves deposits directly, though clearing therapies are being tested. Current treatment stops new amyloid forming; the body then removes deposits very slowly, and organ function can stabilise or improve modestly, especially when treatment starts early.
Why did my carpal tunnel matter?
Amyloid often settles in the wrist's flexor tendons years before it affects the heart, so carpal tunnel syndrome — especially in both wrists, in someone in later life — can be the earliest visible sign of ATTR amyloidosis. Surgeons increasingly send the removed tissue for amyloid staining.
Is amyloidosis a cancer?
AL amyloidosis is related to a blood-cell disorder and is treated by haematology teams, sometimes with chemotherapy, but the clone is usually small and slow-growing — it is not the same as myeloma, though the two can overlap. ATTR amyloidosis is not a cancer at all.
More in Letter A
Related
Sources
- Amyloidosis (MedlinePlus)
- Amyloidosis (National Organization for Rare Disorders (NORD))
- Amyloidosis — Genetic and Rare Diseases Information Center (NIH GARD)
This guide is general information, not medical advice. Rare diseases are individual — diagnosis and treatment depend on your own results, other conditions, and treatment history, and are set by your treating team. Never start, stop, or change a medicine because of something you read here. If you have severe breathlessness, uncontrolled bleeding, confusion, sudden weakness, or thoughts of harming yourself, seek urgent care. Amyloidosis care belongs in specialist centres; treatment differs completely by type, so typing must come first.